Suspension of trading

NeuBase Therapeutics, Inc. Stock

O7P

US64132K2015

Biotechnology & Medical Research

Delayed Deutsche Boerse AG 09:03:16 13/05/2024 +03			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.14M 1.04M 949K 1.79M 121M 1.84M 12.51M 5M 63.95M 4.8M 4.69M 202M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.14M 1.04M 949K 1.79M 121M 1.84M 12.51M 5M 63.95M 4.8M 4.69M 202M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: NeuBase Therapeutics, Inc.

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
27/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
29/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	01/11/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	04/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-43.23%	1.39M
WUXI APPTEC CO., LTD.	+3.80%	+8.10%	+63.78%	+77.70%	69.4B
ARGENX SE	+0.07%	+1.39%	+12.75%	+75.17%	57.24B
LONZA GROUP AG	+1.63%	+4.93%	+24.89%	+104.31%	57.62B
IQVIA HOLDINGS INC.	+0.41%	-3.70%	+26.06%	+34.32%	43.65B
BEONE MEDICINES AG	+2.51%	+4.22%	+20.49%	+110.71%	44.03B
REVOLUTION MEDICINES, INC.	-11.04%	-6.63%	+199.38%	+701.67%	38.08B
CELLTRION, INC.	+7.50%	+13.58%	+29.07%	+64.46%	36.31B
GENMAB A/S	+1.59%	-4.04%	+97.66%	+79.95%	32.61B
WUXI BIOLOGICS (CAYMAN) INC.	-1.68%	+7.64%	+36.80%	-4.43%	25.47B
Average	+0.43%	+2.10%	+51.09%	+120.06%	40.44B
Weighted average by Cap.	+0.87%	+3.12%	+52.91%	+132.61%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company